Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensitizing Potential of CCP-020 (Diacerein 1%) in Healthy Subjects
NCT03472547Phase 1Completed
- Sponsor
- Castle Creek Biosciences
- Start
- Jan 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AC-203 in epidermolysis bullosa simplex (EBS), sponsored by Castle Creek Biosciences. Primary endpoint: Observed Sensitization at 56 days. Started Jan 2018; status: completed.
02
Drugs
AC-203
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NCT03472547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472547.